Donor immune cells show promise against returning blood cancers

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: PROCUREMENT * Group A: CD19+ B-ALL undergoing allogeneic HSCT or Group B: CD19+ B cell CLL or NHL undergoing allogeneic HSCT * Life expectancy of ≥12 weeks. * Patient has an appropriate donor identified for hematopoietic stem cell transplantation TREATMENT * Any patient regardless of sex or age with CD19+ B-ALL undergoing allogeneic HSCT (Group A) OR any patient regardless of sex or age with CD19+ B-CLL or NHL undergoing allogeneic HSCT (Group B) * Residual disease at the time of transplant (bulky or minimal) or post transplant relapse as evidenced by PCR positivity, specific cytogenetic abnormalities, an abnormal population on flow cytometry or increased blasts on bone marrow biopsy or in the peripheral blood. MRD will be defined as detection in blood or marrow of any of the following: * Any leukemia specific marker (such as t(9:22) or t(4:11)) documented in the patient's leukemia cells pre transplant on a post transplant evaluation. * An immune globulin rearrangement known to be a disease marker for this patient post transplant. * A leukemia specific phenotype post transplant at a level of ≥ 0.01% * Mixed donor chimerism (any level) * Life expectancy ≥ 6 weeks * Karnofsky/Lansky score ≥ 50%. * Bilirubin ≤ 2 times the upper limit of normal. * AST ≤ 3 times the upper limit of normal. * Estimated GFR \> 50 mL/min * Hgb ≥ 7.0 (can be a transfused value) * Pulse oximetry of \> 90% on room air * Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after ATL infusion. The male partner should use a condom. * Available allogeneic activated peripheral blood T cell products with \>=15% expression of CD19.CAR-CD28ζ determined by flow cytometry (cell dose is based on total cell numbers and not individual antileukemic cell numbers). * No other investigational antitumor therapy for one month prior to entry in this study. * Patients or legal guardians must sign an informed consent. Exclusion Criteria: * Severe intercurrent infection. * Evidence of GVHD \> grade II. * Pregnant or lactating. * History of hypersensitivity reactions to murine protein-containing products. * Currently taking corticosteroids (\>0.5 mg/kg/day prednisone or equivalent) for therapy of GVHD.